TEVA (Pharmaceuticals) Stock Valuation & Fair Value Significantly overvalued
TEVA (Pharmaceuticals) trades at a blended P/E of 16.3, about 77% above its historical normal valuation, with a forward growth estimate of 20.0% and a PEG of 0.81. Analysts' one-year estimates have been hit 82% of the time.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.
- Price $39.01 at the 2026-09-23 close, 3.5% above the 20-day average ($37.68) and 9.5% above the 50-day ($35.63).
- RSI (14) at 59.1.
- 52-week range $18.34 to $40.06: the price is 2.6% below the high and 112.7% above the low.
Valuation flags
- Overvalued by 77%
Frequently asked questions
Is TEVA overvalued?
At a blended P/E of 16.3 versus its historical normal P/E of 9.2, TEVA trades about 77% above its typical valuation, with a PEG of 0.81 on 20.0% forward growth. tickerseer currently rates it significantly overvalued.
What is TEVA's fair value and PEG?
TEVA trades at a blended P/E of 16.3 against a historical normal P/E of 9.2, a PEG of 0.81, and a forward growth estimate of 20.0%.
Has tickerseer's rating of TEVA changed?
tickerseer's rating has been significantly overvalued since 2026-09-21.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.